Skip to main content

Table 3 Results of the multivariable Cox model for progression-free survival (PFS) and overall survival (OS)

From: Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry

Model for PFS

Risk/baseline category

Beta

HR

95% CI

p-value

Number of metastatic sites

2/1

0.29

1.34

1.22-1.46

<0.001

 

3 and more/1

0.53

1.70

1.50-1.94

<0.001

Presence of metastasis at diagnosis

M1/M0

0.12

1.13

1.03-1.23

0.008

Site of primary tumour

Rectum/Colon

0.09

1.10

1.01-1.19

0.04

Age

65-75 years/<65 years

−0.01

0.99

0.91-1.09

0.88

 

>75 years/<65 years

0.01

1.01

0.81-1.25

0.96

Model for OS

Risk/baseline category

Beta

HR

95% CI

p-value

Number of metastatic sites

2/1

0.34

1.41

1.25-1.59

<0.001

 

3 and more/1

0.66

1.94

1.65-2.27

<0.001

Presence of metastasis at diagnosis

M1/M0

0.23

1.25

1.12-1.41

<0.001

Site of primary tumour

Rectum/Colon

0.12

1.13

1.01-1.26

0.03

Age

65-75 years/<65 years

−0.02

0.98

0.87-1.11

0.73

 

>75 years/<65 years

0.17

1.18

0.89-1.56

0.24

  1. Abbreviations: HR: hazard ratio; CI: confidence interval.